- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05151367
SMS HPV Vaccine Reminders (SEARCH)
July 3, 2024 updated by: Melissa Stockwell, Columbia University
SEARCH: Short Message Service (SMS) Electronic Adolescent Reminders for Completion of HPV Vaccination - Uganda: Pilot
This study will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic, also in Kampala.
While text messages can be used in populations with low literacy, families can opt to receive automated phone call reminders instead.
The investigators will pilot assess the impact of vaccine reminders on human papillomavirus (HPV) vaccination.
Caregivers of preteens/adolescents will be randomized and stratified by site, language and HPV vaccine dose needed (initiation vs. completion).
As this is a feasibility trial, the investigators expect to measure effect size but not necessarily achieve statistical significance.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cervical cancer is the leading female cancer in Uganda.
Many women are diagnosed with late-stage disease, and 80% of women die within 5 years of diagnosis, making primary prevention critical.
HPV is the principal cause of cervical cancer, making vaccination the single most important primary preventive measure.
The national HPV vaccination program in Uganda began in November 2015 and focuses solely on preteen/adolescent girls.
Two strategies have been adopted for the multi-dose series: 1) school-based and 2) community-based.
However, in Kampala, only 29% of girls receive both needed doses.
Reasons for undervaccination include school absenteeism on special vaccination days for those receiving vaccination as part of a school program, failing to remember to come to a health facility for a needed dose for those being vaccinated in the community, and lack of knowledge regarding HPV and the vaccines including vaccine misperceptions.
While research regarding the use of text message vaccine reminders is strong in the U.S., their use has not yet been demonstrated in a preteen/adolescent population in Sub-Saharan Africa and other low and middle income countries (LMICs).
According to the World Bank, currently 89.9% of urban households in Uganda have a cell phone.
Study Type
Interventional
Enrollment (Actual)
154
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kampala, Uganda
- Makerere University/Mulago Hospital
-
-
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 14 years (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Be a parenting adult of an adolescent girl aged 10-14 years
- Reside in Kampala and/or the surrounding districts
- Speak English or Luganda
- Have a cell phone with text messaging capability
- Must have ability to consent
Exclusion Criteria:
- Parenting adult speaks other language than English or Luganda only
- Parenting adult already enrolled in the study for another child
- Participation in pretesting activities
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Text message reminders
|
Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
|
|
No Intervention: Usual Care
No reminders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Received the Next HPV Vaccine Dose
Time Frame: Up to 6 months from randomization
|
Timeliness of vaccination will be measured by the number of participants who received the next HPV vaccine dose.
|
Up to 6 months from randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Melissa S. Stockwell, MD, MPH, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 23, 2022
Primary Completion (Actual)
October 30, 2022
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
November 26, 2021
First Submitted That Met QC Criteria
November 26, 2021
First Posted (Actual)
December 9, 2021
Study Record Updates
Last Update Posted (Actual)
July 8, 2024
Last Update Submitted That Met QC Criteria
July 3, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- AAAT1572
- 1R21CA253604-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papillomavirus Vaccination
-
Columbia UniversityNational Cancer Institute (NCI); Makerere UniversityActive, not recruiting
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHuman Papillomavirus VaccinationUnited States
-
Plan A Health, IncMerck Sharp & Dohme LLCEnrolling by invitationHuman Papillomavirus VaccinationUnited States
-
International Agency for Research on CancerEnrolling by invitationHuman Papillomavirus VaccinationFrance
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHuman Papillomavirus VaccinationUnited States
-
University of PennsylvaniaCompletedVaccine Refusal | Vaccination Hesitancy | Human Papillomavirus VaccinationUnited States
-
Milton S. Hershey Medical CenterRecruiting
-
Ankara Medipol UniversityCompletedHuman Papillomavirus (HPV) Vaccination | Message Framing | Vaccination IntentionTurkey (Türkiye)
-
University of VirginiaRecruitingHuman Papillomavirus Infection | Vaccination HesitancyUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteMerck Sharp & Dohme LLCCompleted
Clinical Trials on Text message reminder
-
Sarah HufCompletedCervical Carcinoma | Cervical DysplasiaUnited Kingdom
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Recruiting
-
Brigham and Women's HospitalUniversity of WaterlooCompleted
-
St. Louis UniversityTerminated
-
Wayne State UniversityRecruitingHypertension | High Blood PressureUnited States
-
University of South FloridaTerminatedDiabetes, GestationalUnited States
-
Stanford UniversityNot yet recruiting
-
Stanford UniversityCompleted
-
University of Southern CaliforniaCompleted
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkActive, not recruitingHPV VaccinationUnited States